Alnylam Pharmaceuticals Inc Revenue 2008–2025
Alnylam Pharmaceuticals Inc annual/quarterly revenue history and growth rate from 2008 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Alnylam Pharmaceuticals Inc revenue for the quarter ending September 30, 2025 was 1.2 B, a 149.35% increase year-over-year.
- Alnylam Pharmaceuticals Inc revenue for the twelve months ending September 30, 2025 was 3.1 B, a 40.23% increase year-over-year.
- Alnylam Pharmaceuticals Inc annual revenue for 2025 was 3.7 B, a 65.19% increase from 2024.
- Alnylam Pharmaceuticals Inc annual revenue for 2024 was 2.2 B, a 22.97% increase from 2023.
- Alnylam Pharmaceuticals Inc annual revenue for 2023 was 1.8 B, a 76.23% increase from 2022.
- Alnylam Pharmaceuticals Inc annual revenue for 2022 was 1.0 B.
Alnylam Pharmaceuticals Inc (ALNY) — Frequently Asked Questions
Alnylam Pharmaceuticals Inc (ALNY) is a publicly traded US company. It has a market capitalization of $39.28B. In fiscal 2025 it reported revenue of $3.71B and net income of $314M. Explore ALNY's stock price, financial statements, earnings history, margins and key ratios below.
What is Alnylam Pharmaceuticals Inc's market cap?
Alnylam Pharmaceuticals Inc (ALNY) has a market capitalization of $39.28B.
What is the ALNY stock price?
ALNY trades at $291.63 (+0.14% on the day).
How much revenue does Alnylam Pharmaceuticals Inc make?
Alnylam Pharmaceuticals Inc reported revenue of $3.71B in fiscal 2025.
Is ALNY profitable?
In fiscal 2025, Alnylam Pharmaceuticals Inc reported net income of $314M.